← boardnext 2026-08next 2026-08
IVVD
Invivyd, Inc.distress 4/10 · elevated risk$0.61-2%today-79% from 52w high
Infectious Disease 1
Lead: COVID-19
Revenue
$14M
Liquidity
$184M
Runway
2.3 yrs
Shares 1y
+145%
Price & events
-72.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-22.6%
1W
-34.8%
1M
-59.6%
3M
-71.1%
6M
-23.7%
1Y
-51.2%
2Y
—
5Y
-97.1%
All
Overview
- Market Cap
- $179.71M
- Volume
- 143.51K
- 52 Week Range
- $0.52 – $2.88
- Total Shares
- 294.61M
- Float Shares
- 214.30M
- Short %
- 10.29%
- % Held by Insiders
- 7.07%
- % Held by Institutions
- 83.98%
- RVOL
- 0.03x
- Beta
- 0.67
Pipeline stages · 2 programs
VYD2311-SD, VYD2311-MD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
COVID-19 mRNA vaccine, VYD2311
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | VYD2311-SD, VYD2311-MDfast track | COVID-19 | — | active not recruiting |
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | COVID-19 mRNA vaccine, VYD2311 | COVID-19 | — | recruiting |
| 2025-05 | Phase 1 | VYD2311fast track | COVID-19 | 40 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 18
- late 2026Guided 40%regulatory submissionFiled (NDA/BLA)VMS063 · Target IND readiness for VMS063.SEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)VBY329 · Targeting IND readiness for VBY329SEC 8-K
- Q3 2026Guided 70%readoutPhase 3VYD2311 · Topline data from DECLARATION pivotal trialSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-06withdrawalPEMGARDA · FDA issued notice of EUA termination effective June 29, 2027.SEC 8-K
- mid-2026readoutPhase 3VYD2311 · Top-line data from DECLARATION and LIBERTY trialsSEC 8-K
- mid-2026trial initiationsecondaryPhase 2VYD2311 · Phase 2 trial of VYD2311SEC 8-K
- 2026-04-09fda agreementVYD2311 · FDA alignment on Initial Pediatric Study Plan for DRUMMER study.SEC 8-K
- 2026-02-01fda agreementVYD2311 · FDA aligned on LIBERTY Phase 3 trial design comparing VYD2311 to mRNA vaccineSEC 8-K
- by end of yearreadoutmeasles mAb · Progress update on discovery program.SEC 8-K
- around year-end 2025trial initiationsecondaryPhase 3VYD2311 · LIBERTY trial to evaluate safety and tolerability of VYD2311 with mRNA vaccines.SEC 8-K
- 2025-10-06fda agreementVYD2311 · FDA cleared IND and provided alignment on pivotal clinical programSEC 8-K
- 2025-08-14fda agreementVYD2311 · FDA alignment on rapid BLA pathway for VYD2311 to protect from COVID-19SEC 8-K
- 2025-07-02partnershippemivibart, VYD2311 · Formed SPEAR Study Group with Drs. Peluso, Proal, and Putrino to evaluate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome.SEC 8-K
- later in Q2 2025readoutPhase 1VYD2311 · Phase 1 clinical trial data read-out including potency, half-life and full safety unblinding.SEC 8-K
- 2025-02-24crlPEMGARDA (pemivibart) · FDA declined request to expand EUA to include treatment of mild-to-moderate COVID-19 for immunocompromised personsSEC 8-K
- late August 2024trial initiationsecondaryPhase 1VYD2311 · First-in-human clinical trial dosing scheduled to begin late AugustSEC 8-K
- 2024-08-27fda agreementpemivibart · FDA updated PEMGARDA Fact Sheet for Healthcare Providers including exploratory efficacy data.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+1539% upside) · 3 analysts
- 2026-07-07BTIGBuy
- 2026-06-15HC Wainwright & Co.Buy
- 2026-06-09BTIGBuy
- 2026-06-01BTIGBuy
- 2026-05-18BTIGBuy
- 2026-02-26BTIGBuy
Competitors — COVID-19
Recent news
- 2026-07-22IVVD stock trades around recent lows as Invivyd highlights COVID-19 antibody pipeline - Ad-hoc-news.de
- 2026-07-17Invivyd stock trades around recent lows as investors weigh antibody revenue outlook - Ad-hoc-news.de
- 2026-07-17IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
- 2026-07-10Invivyd Inc (IVVD) Institutional Confidence - TradingKey
- 2026-07-08H.C. Wainwright reiterates Invivyd stock rating on regulatory path - Investing.com
- 2026-07-06Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA - Stock Titan
- 2026-07-06Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down - Moomoo
- 2026-07-06PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.